Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 7, 2011, Pages 1182-1188

  Patel, Keyur ^a   Thompson, Alexander J ^a   Chuang, Wan Long ^c   Lee, Chuan Mo ^d   Peng, Chen Yuan ^e   Shanmuganathan, Ganesananthan ^f   Thongsawat, Satawat ^g   Tanwandee, Tawesak ^h   Mahachai, Varocha ⁱ   Pramoolsinsap, Chutima ^j   Cho, Mong ^k   Han, Kwang Hyup ^l   Shah, Samir R ^m   Foster, Graham R ⁿ   Clark, Paul J ^a   Pulkstenis, Erik ^b   Subramanian, G Mani ^b   Mchutchison, John G ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f HOSPITAL KUALA LUMPUR   (Malaysia)

^g CHIANG MAI UNIVERSITY   (Thailand)

^h MAHIDOL UNIVERSITY   (Thailand)

ⁱ KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^j MAHIDOL UNIVERSITY   (Thailand)

^k Pusan National University   (South Korea)

^l Yonsei University   (South Korea)

^m JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

ⁿ QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

Caucasian; Ethnic; Hepatitis C virus infection; Liver; Metabolic; Steatosis; Viral hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBINTERFERON ALPHA2B; GAMMA GLUTAMYLTRANSFERASE; RIBAVIRIN; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; DEMOGRAPHY; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HOMEOSTASIS MODEL FOR ASSESSMENT OF INSULIN RESISTANCE; HUMAN; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATHOLOGIST; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 79958783189     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06722.x     Document Type: Article

References (49)

1. Negro F, Clement S. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. J. Viral Hepat. 2009; 16: 681-8.
2. Pazienza V, Clement S, Pugnale P etal. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007; 45: 1164-71.
3. Douglas MW, George J. Molecular mechanisms of insulin resistance in chronic hepatitis C. World J. Gastroenterol. 2009; 15: 4356-64.
4. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann. Intern. Med. 2000; 133: 592-9.
5. Hsu CS, Liu CJ, Liu CH etal. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int. 2008; 28: 271-7.
6. Moucari R, Asselah T, Cazals-Hatem D etal. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-23.
7. Poustchi H, Negro F, Hui J etal. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J. Hepatol. 2008; 48: 28-34.
8. Romero-Gomez M, Del Mar Viloria M, Andrade RJ etal. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
9. Dai CY, Huang JF, Hsieh MY etal. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J. Hepatol. 2009; 50: 712-18.
10. Moucari R, Ripault MP, Martinot-Peignoux M etal. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009; 58: 1662-9.
11. Svegliati-Baroni G, Ridolfi F, Di Sario A etal. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999; 29: 1743-51.
12. Paradis V, Perlemuter G, Bonvoust F etal. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34: 738-44.
13. Hui JM, Sud A, Farrell GC etal. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression (corrected). Gastroenterology 2003; 125: 1695-704.
14. Muzzi A, Leandro G, Rubbia-Brandt L etal. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J. Hepatol. 2005; 42: 41-6.
15. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-8.
16. Taura N, Ichikawa T, Hamasaki K etal. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am. J. Gastroenterol. 2006; 101: 2752-9.
17. Petta S, Camma C, Di Marco V etal. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am. J. Gastroenterol. 2008; 103: 1136-44.
18. Everhart JE, Lok AS, Kim HY etal. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009; 137: 549-57.
19. Veldt BJ, Chen W, Heathcote EJ etal. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008; 47: 1856-62.
20. Camma C, Petta S, Di Marco V etal. Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. Hepatology 2009; 49: 195-203.
21. Rubbia-Brandt L, Quadri R, Abid K etal. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J. Hepatol. 2000; 33: 106-15.
22. Leandro G, Mangia A, Hui J etal. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-42.
23. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
24. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J. Hepatol. 2002; 37: 837-42.
25. Rubbia-Brandt L, Fabris P, Paganin S etal. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004; 53: 406-12.
26. Bochud PY, Cai T, Overbeck K etal. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J. Hepatol. 2009; 51: 655-66.
27. Hourigan LF, Macdonald GA, Purdie D etal. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-19.
28. Patton HM, Patel K, Behling C etal. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J. Hepatol. 2004; 40: 484-90.
29. Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 723-31.
30. Chan JC, Malik V, Jia W etal. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-40.
31. Huang JF, Chuang WL, Yu ML etal. Hepatitis C virus infection and metabolic syndrome-a community-based study in an endemic area of Taiwan. Kaohsiung J. Med. Sci. 2009; 25: 299-305.
32. Chu CJ, Hung TH, Hwang SJ etal. Association of insulin resistance with hepatic steatosis and progression of fibrosis in Chinese patients with chronic hepatitis C. Hepatogastroenterology 2008; 55: 2157-61.
33. Hsu CS, Liu CH, Liu CJ etal. Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection. J. Gastroenterol. Hepatol. 2010; 25: 970-7.
34. Nelson DR, Benhamou Y, Chuang WL etal. Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology 2010; 139: 1267-76.
35. Bonora E, Targher G, Alberiche M etal. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63.
36. Esteghamati A, Ashraf H, Khalilzadeh O etal. Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Nutr. Metab. (Lond) 2010; 7: 1-8.
37. Lee S, Choi S, Kim HJ etal. Cutoff values of surrogate measures of insulin resistance for metabolic syndrome in Korean non-diabetic adults. J. Korean Med. Sci. 2006; 21: 695-700.
38. Lam KD, Bacchetti P, Abbasi F etal. Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: impact of obesity and ethnicity. Hepatology 2010; 52: 38-46.
39. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20.
40. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine-reporting of subgroup analyses in clinical trials. N. Engl. J. Med. 2007; 357: 2189-94.
41. Banerjee S, Saito K, Ait-Goughoulte M, Meyer K, Ray RB, Ray R. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance. J. Virol. 2008; 82: 2606-12.
42. Del Campo JA, Romero-Gomez M. Steatosis and insulin resistance in hepatitis C: a way out for the virus? World J. Gastroenterol. 2009; 15: 5014-19.
43. Harrison SA. Correlation between insulin resistance and hepatitis C viral load. Hepatology 2006; 43: 1168.
44. Thompson AJ, Patel K, Tillmann HL etal. Sustained virologic response 15 independently associated with improvement in insulin resistance in genotype 1, but not genotype 2/3, chronic Hcv patients. Hepatology 2009; 50: 358a-9a.
45. Ye J. Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog. 2007; 3: e108.
46. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J. Hepatol. 2001; 34: 428-34.
47. Petit JM, Benichou M, Duvillard L etal. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am. J. Gastroenterol. 2003; 98: 1150-4.
48. Sud A, Hui JM, Farrell GC etal. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004; 39: 1239-47.
49. Forns X, Ampurdanes S, Llovet JM etal. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.